Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: EyePoint, Inc.

Market Cap 1.03B 895M 825M 772M 1.44B 98.48B 1.47B 9.8B 3.8B 47.7B 3.88B 3.8B 166B P/E Ratio 2026 *
-3.48x
P/E Ratio 2027 * -4.43x
Enterprise Value 739M 640M 590M 552M 1.03B 70.44B 1.05B 7.01B 2.72B 34.12B 2.78B 2.72B 119B EV / Sales 2026 *
433x
EV / Sales 2027 * 16.5x
Free-Float
96.32%
Yield 2026 *
-
Yield 2027 * -
1 day+4.76%
1 week-0.08%
Current month-9.20%
1 month-9.74%
3 months-20.14%
6 months-26.26%
Current year-32.51%
1 week 11.3
Extreme 11.295
12.41
1 month 11.3
Extreme 11.295
14.02
Current year 11.3
Extreme 11.295
18.87
1 year 7.94
Extreme 7.94
19.11
3 years 3.91
Extreme 3.91
30.99
5 years 2.19
Extreme 2.19
30.99
10 years 2.19
Extreme 2.19
42.5
Manager TitleAgeSince
Chief Executive Officer 68 2023-07-09
Director of Finance/CFO 61 2019-11-13
Chief Tech/Sci/R&D Officer 43 2024-03-03
Director TitleAgeSince
Director/Board Member 68 2023-07-09
Director/Board Member 80 2024-09-02
Director/Board Member 58 2019-07-14
Date Insider Type Main position Quantity % Market Cap.
May. 24Fiscal year

Chief Financial Officer

18,627 0.0222%
Apr. 16Fiscal year

Chief Technology Officer

7,311 0.0088%
Mar. 22Others

Chief Executive Officer

453,532 0.5478%
Change 5-day change 1-year change 3-year change Capi.($)
+4.76%-0.08%+33.88%+103.80% 1.03B
-0.73%+5.34%+40.78%+154.77% 1,013B
+0.63%+6.83%+52.44%+49.05% 574B
-0.21%+3.60%+18.71%+62.79% 397B
-0.72%+4.97%+21.24%+15.95% 324B
+0.39%-0.44%+23.73%+14.07% 280B
+0.64%+3.12%+23.15%+31.51% 273B
-1.98%-0.14%+15.10%+54.38% 182B
-1.19%-1.83%-46.07%-49.06% 194B
-3.20%-5.82%+10.35%+55.50% 151B
Average -0.16%+1.77%+19.33%+49.28% 338.97B
Weighted average by Cap. -0.44%+3.99%+27.76%+69.78%

Financials

2026 *2027 *
Net sales 1.71M 1.48M 1.36M 1.27M 2.38M 163M 2.43M 16.18M 6.28M 78.76M 6.41M 6.27M 274M 47.71M 41.29M 38.06M 35.61M 66.45M 4.54B 67.94M 452M 175M 2.2B 179M 175M 7.65B
Net income -311M -269M -248M -232M -433M -29.64B -443M -2.95B -1.14B -14.36B -1.17B -1.14B -49.92B -266M -230M -212M -199M -371M -25.36B -379M -2.52B -979M -12.28B -999M -978M -42.71B
Net Debt -294M -255M -235M -220M -410M -28.04B -419M -2.79B -1.08B -13.58B -1.1B -1.08B -47.23B -248M -215M -198M -185M -346M -23.65B -354M -2.35B -913M -11.45B -932M -912M -39.83B
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
214
Date Price Change Volume
26-06-10 12.33 $ +4.76% 1,161,652
26-06-09 11.77 $ +2.79% 1,874,484
26-06-08 11.45 $ -2.80% 805,677
26-06-05 11.78 $ -3.92% 925,249
26-06-04 12.26 $ -0.65% 815,092
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
12.33USD
Average target price
37.00USD
Spread / Average Target
+200.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EYPT Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!